Pomerantz Law Firm Investigates Claims Against Omeros Corporation
Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation following the company's receipt of a negative opinion from the European Medicines Agency.
Pomerantz LLP, a law firm specializing in securities litigation, is investigating potential claims against Omeros Corporation concerning alleged securities fraud or other unlawful business practices. The investigation focuses on the actions of the company and its officers and/or directors.
The probe was initiated after Omeros announced on June 26, 2026, that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on the company's marketing authorization application for narsoplimab. The drug is intended for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).
Following this announcement, Omeros' stock price declined by $2.05, or 19.12%, to close at $8.67 per share on June 26, 2026. Investors who purchased Omeros securities and wish to learn more are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Pomerantz LLP, with offices in New York and other international locations, has a history of pursuing class action litigation and recovering damages for investors. The firm encourages those who may have relevant information or concerns to contact them for further details regarding the potential class action.